ortho-Quinone tanshinones directly inhibit telomerase through an oxidative mechanism mediated by hydrogen peroxide by Soares, Joana et al.
Ortho-Quinone tanshinones directly inhibit telomerase through
an oxidative mechanism mediated by hydrogen peroxide
Joana Soares, Brian R. Keppler, Xihong Wang, Kuo-Hsiung Lee, and Michael B. Jarstfer
aEshelman School of Pharmacy, Division of Chemical Biology and Medicinal Chemistry,
University of North Carolina, Chapel Hill, North Carolina 27599-7568
Abstract
The tanshinone natural products possess a variety of pharmacological properties including anti-
bacterial, anti-inflammatory, anti-oxidant, and anti-neoplastic activity. The molecular basis of
these effects, however, remains largely unknown. In the present study, we explored the direct
effect of tanshinones on the enzyme telomerase. Telomerase is up-regulated in the majority of
cancer cells and is essential for their survival, making it a potential anti-cancer drug target. We
found that the ortho-quinone tanshinone II-A inhibits telomerase in a time- and DTT-dependent
fashion, and the hydrogen peroxide scavenger catalase protected telomerase from inactivation.
These findings demonstrate that ortho-quinone containing tanshinones can inhibit telomerase
owing to their ability to generate reactive oxygen species. The results also provide evidence that
telomerase is directly and negatively regulated by reactive oxygen species.
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Tanshinones, diterpenes isolated from the root of Salvia miltiorrhiza, have been widely used
in Asia for the treatment of numerous disorders (cardiovascular and inflammatory diseases,
hepatitis, and cancer) and exhibit diverse pharmacological properties (anti-oxidant, anti-
inflammatory, and anti-cancer activity) (Figure 1).1 Although the mechanisms of these
effects have been explored, accurate details remain elusive. Proposed mechanisms for the
biological activity of tanhinones include DNA binding2 and induced intracellular production
of reactive oxygen species.3 Despite these recent advances, the molecular basis of
tanshinone activity remains poorly understood. Because telomerase is up-regulated in the
majority of cancer cells and can directly affect apoptosis, we hypothesized that telomerase
may be a key molecular target of tanshinones. Indeed, it was recently reported that
tanshinone treatment can lead to decreased cellular telomerase activity commensurate with
reduced levels of hTERT mRNA, the catalytic telomerase subunit.4 However, the
pleiotropic effects of tanshinones preclude potential direct effects on telomerase to be
determined from current reports.
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Telomerase is a ribonucleoprotein complex that uses its RNA subunit to synthesize the
repetitive G-rich DNA, 5′-TTAGGG/3′-AATCCC in humans, found at each 3′
chromosome end.5 Telomerase activity is present in the overwhelming majority of cancer
cells and normal proliferative cells such as stem cells, but tends to be absent from human
somatic cells.6 In the absence of telomerase, the termini of chromosomes, called telomeres,
are not efficiently replicated.7 As a result of this end-replication problem, cells require active
telomerase for persistent replication.8 Telomerase promotes tumorigenicity in part by
helping maintain telomeric DNA length to overcome replicative senescence. Additionally,
other functions of telomerase beyond the chromosome ends have been suggested to
contribute to tumorigenesis.9 Notably, telomerase appears capable of inhibiting apoptosis by
mechanisms independent of telomeric DNA synthesis10, 11 and can promote proliferation
through the Wnt pathway.12 Pharmacological agents that inhibit telomerase with defined
mechanisms would be useful agents to study telomerase biology and may serve as leads for
therapeutic development. Here, we describe our characterization of the direct effect of
several tanshinones on telomerase enzymatic activity.
We used a telomerase assembly assay13 to test the effect of tanshinones on telomerase. The
assembly assay allows identification of small molecules that affect telomerase through
several mechanisms including direct inhibition of its enzymatic activity, blocking specific
required protein-RNA interactions,13 and inhibiting the chaperone hsp90, which is required
to reconstitute telomerase activity in viro.14, 15 In telomerase assembly assays, Tan II-A
(75% inhibition at 50 µM), Tan I (65% inhibition), and cryptotanshinone (75% inhibition),
which contain ortho-quinone C rings, inhibited telomerase, whereas neo-tanshinlactone
(25% inhibition), which has a lactone C ring, was a significantly less effective inhibitor.
This suggests that the ortho-quinone moiety found in some tanshinones is a critical
requirement for telomerase inhibition. The results also showed that an aromatic A ring
(compare tanshinone I to Tan II-A) and a heteroaromatic D ring (compare Tan II-A to
cryptotanshinone) are not required for telomerase inhibition.
Since Tan II-A directly inhibited telomerase, we determined if Tan II-A cytotoxicity
correlated with telomerase. As expected, Tan II-A was a potent cytotoxin of a telomerase
positive breast cancer cell line, MCF-7 (EC50 = 0.90 µM), and a prostate cancer cell line,
PC-3 (EC50 = 1.2 µM), consistent with previous reports.1, 16–18 Furthermore, telomerase
activity was reduced 50% in MCF-7 cells 24 hr after exposure to 3 µM Tan II-A (data not
shown), confirming results with the structurally related Tan I-A reported by Liu et al.4
Telomerase negative GM847 and Saos-2 cell lines were less sensitive to Tan II-A
cytotoxicity (EC50 of >20 µM).
To examine the importance of the ortho-quinone moiety, we examined telomerase inhibition
by Tan II-A and the simple ortho-quinone 9,10-phenanthrenequinone (PHQ). Tan II-A and
PHQ were equipotent inhibitors (IC50 = 5.0 µM in the assembly assay) of telomerase (Figure
2). Both Tan II-A and PHQ were also inhibitors of pre-assembled telomerase (IC50 = 0.5
µM) (Figure 2). However, the compounds only partially inhibited telomerase activity when
added to preassembled telomerase with the maximum amount of inhibition ~30% for Tan II-
A ~50% for PHQ, compared to >95% when added before assembly.
It is well documented that reactive oxygen species (ROS) are formed in the presence of a
reducing agent (such as DTT), oxygen, and catalytic amounts of ortho-quinones capable of
undergoing redox cycling.19, 20 This lead to the hypothesis that redox cycling is responsible
for Tan II-A inhibition of telomerase. If redox cycling is responsible for inhibition, we
would expect inhibition to be time and DTT dependent. To test this, we incubated purified
pre-assembled telomerase with PHQ and varying concentrations of DTT for increasing time
periods followed by a direct telomerase assay. Telomerase activity was inhibited by ~35%
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when pre-incubated with DTT (5 mM) for 5 min; however, it was >95% inhibited when
telomerase was incubated in the presence of DTT for 60 min (Figure 3). We also found that
DTT concentration directly correlated with extent of inhibition (Figure 3B). These findings
are in agreement with results from Bova et al. showing that inactivation of protein tyrosine
phosphate α by ortho-quinone compounds is greatly enhanced by DTT and that inhibition
correlated with hydrogen peroxide generation.21 The time and DTT dependence of PHQ
inhibition of telomerase are consistent with the hypothesis that telomerase inhibition by
ortho-quinones is mediated by ROS. The concentration of free thiols, in particular
glutathione, in cells is 1–5 mM, so the concentration of DTT used here is relevant to cellular
conditions.
Because catalase is a hydrogen peroxide scavenger, we investigated its ability to protect
telomerase from ortho-quinone generated ROS. We pre-incubated purified telomerase with
PHQ, DTT, and catalase for 1 hour before performing a telomerase assay. As predicted,
catalase completely protected telomerase (Figure 4). In order to test if the inactivation of
telomerase by PHQ is reversible, purified telomerase was pre-incubated with PHQ and DTT
for 1 hour prior to the addition of catalase. We found that the addition of catalase after 1
hour did not rescue telomerase activity, suggesting that inactivation is irreversible (Figure 4,
lane 4).
The observation that catalase can protect telomerase from ortho-quinone inhibition raised
the possibility that ortho-quinone tanshinones produce reactive oxygen species such as
superoxide and hydrogen peroxide that could subsequently inactivate telomerase. To
examine this possibility, we incubated Tan II-A and PHQ separately with DTT in PBS and
monitored the production of hydrogen peroxide. Tan II-A generated hydrogen peroxide in a
time-dependent fashion that plateaued at 60 min resulting in the formation of ~2.5 mM
hydrogen peroxide (Figure 5). In contrast, when Tan II-A was incubated in PBS alone
without DTT, hydrogen peroxide formation was not observed. Additionally, incubation with
catalase completely blocked hydrogen peroxide production as expected.
The results of this study reveal that ortho-quinone containing tanshinones are telomerase
inhibitors owing to their ability to engage in redox cycling leading to hydrogen peroxide
production. These findings have important implications for the clinical use of tanshinones
and reveal for the first time that telomerase itself is a biologically significant and direct
target of ROS. The results also add to the growing evidence that induction of ROS is a
primary mechanism of Tan II-A biological activity.3, 22 Given that the ROS induction we
observed is directly related to the concentration of reducing equivalent DTT, we predict that
the ability to generate ROS in cells may be similarly controlled by cellular redox
environment, which may help to explain the pleiotropic effects of Tan II-A and other
tanshinones. The cell-based assays reported here suggest that Tan II-A is cytotoxic to both
telomerase-positive and telomerase-negative cells, but that telomerase-positive cell lines
were more sensitive to Tan II-A than telomerase-negative cells. Initially we considered that
this was due to oncogenic addiction of telomerase by the telomerase-dependent cancer cells.
However, the realization that Tan II-A is redox active leads to the hypothesis that the
cytotoxicity profile observed is dependent on the levels of reducing agents and thus the
redox environment of the cells. It is known that the redox environment of cancer cells is
imbalanced so it is likely that redox active compounds like Tan II-A will have varying
effects on cells dependent on redox status.23 Interestingly, tanshinones act as anti-oxidants
in some cells, perhaps by affecting transcription of key anti-oxidant genes.24
It is clear that Tan II-A inhibits in vitro reconstituted recombinant telomerase through direct
ROS damage, but the effects of Tan II-A on cellular telomerase may be an indirect or a
direct effect of ROS. Tan II-A has been shown to affect several biological targets and has
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diverse biological activity.1 For example, Tan II-A inhibits expression of genes required for
osteoclast differentiation and activity while not inducing apoptosis.25 Another study showed
that Tan II-A-induced apoptosis of human hepatocellular carcinoma cells coincides with up-
regulation of pro-apoptotic proteins fas, bax, and p53 concomitant with down-regulation of
bcl2, and c-myc.16 Decreased c-myc activity could account for the decreased telomerase
activity in Tan II-A treated cells since c-myc regulates hTERT transcription.26 These and
other cell-type dependent Tan II-A effects1 presumably arise from its ability to affect several
targets perhaps through several mechanisms: ROS (such as hydrogen peroxide generation),
DNA binding, and possibly direct protein binding. As a result, tanshinones and other ortho-
quinone compounds capable of redox-cycling are poor leads for a target-based drug
discovery approach since ROS undoubtedly affects many cellular targets.
We conclude that the mechanism of telomerase inhibition by Tan II-A is ROS dependent,
providing evidence that telomerase is directly regulated by ROS. It is known that increased
ROS can accelerate telomere loss in diverse cell types.27 Although telomere loss occurs
naturally with each round of DNA replication, telomere shortening can be accelerated by the
presence of ROS, which has been attributed to oxidation of telomeric DNA. In addition,
telomerase activity was reported to be sensitive to oxidative stress in endothelial28–30 and
vascular smooth muscle cells,31 commensurate with accelerated telomere loss. Several
mechanisms for ROS-dependent telomerase inhibition can be considered and there is
evidence for decreased transcription of telomerase RNA32 and hTERT.33 In addition, the
potential effects of cellular ROS on telomerase are complicated by the observation that the
subcellular location of telomerase is ROS sensitive.34, 35 For example, hTERT appears
excluded from or transported out of the nucleus and can localize to the mitochondria in
mildly stressed cells. Evidence that telomerase can, in different cells, protect the
mitochondria from ROS36 or enhances ROS damage to mitochondrial DNA37 have been
reported. Telomeric DNA has also been shown to be sensitive to oxidative stress,38, 39 but
there is no reported evidence suggesting that ROS can directly inhibit telomerase.
The results here contribute to the mechanistic understanding of ROS induced telomere
dysfunction by showing that ROS directly inhibits telomerase. While ROS can affect many
cellular targets, it is likely that mild ROS induced telomere dysfunction is an important
contributor to negative ROS effects. ROS-induced telomere dysfunction appears to occur by
multiple mechanisms: inhibition of telomerase, changes in the subcellular telomerase
location, and damage to telomeric DNA. Current studies are underway to identify the redox-
sensitive residues in the telomerase complex and to examine the biological significance of
the telomerase sensitivity to ROS. The findings reported here suggest a critical role of
oxidative damage to telomerase in cellular aging and in cancer cell biology and portend a
role of ROS and perhaps reactive nitrogen species in regulating telomerase.
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Tan II-A and PHQ inhibit telomerase. (A) Telomerase inhibition by Tan II-A in an assembly
assay. hTERT and hTER were incubated with Tan II-A (0.1, 0.5, 1, 5, 10, 50 and 100 µM) in
an assembly assay. hTERT was translated in rabbit reticulocyte lysates and incubated with
in vitro transcribed hTER 1.5 h in the presence of inhibitor. Telomerase activity was then
determined by direct primer extension assay.13 Telomerase products were resolved by gel
electrophoresis, imaged by phosphorimaging, and quantified using ImageQuant. Percent
telomerase activity was determined by comparison with a positive control containing DMSO
as a carrier and products were normalized to a loading control (LC), which is a 100 nt 32P-
labeled DNA oligonucleotide used to control for recovery and loading irregularities. (B)
Inhibition of assembled telomerase by Tan II-A. Telomerase was reconstituted in rabbit
reticulocyte lysate then assayed (post-assembly) by the direct primer-extension protocol in
the presence of Tan II-A (0.06, 0.3, 0.6, 3, 6, 30, 60 and 300 µM). (C) Quantification of
telomerase assays. The curve with ● symbols is data from the assembly assay, while the
curve with ○ symbols is data from the post-assembly assay. Raw activity levels were
obtained by gel analysis using ImageQuant and normalized to loading controls. (D)
Telomerase inhibition by PHQ in an assembly assay. hTERT and hTER were incubated with
PHQ (0.001, 0.1, 1, 10, 50 and 100 µM) for 1.5 h before telomerase activity was detected by
direct primer extension assay. (E) Inhibition of pre-assembled telomerase by PHQ.
Telomerase was reconstituted in rabbit reticulocyte lysate then assayed by direct primer-
extension in the presence of PHQ (0.001, 0.1, 1, 10, 50 and 100 µM). (F) Quantification of
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telomerase assays. The curve with ● symbols is data from the assembly assay, while the
curve with ♦ symbols is data from the post-assembly assay. Data in C and E are from at least
three independent experiments and standard deviation is shown.
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Inhibition of telomerase by PHQ is time and DTT dependent. (A) Reconstituted telomerase
was pre-incubated with or without PHQ (50 µM) and DTT (5 mM) for either 5 min or 60
min before telomerase activity was determined. Lane 1, DMSO only; lane 2, 5 min
incubation with DTT and PHQ; lane 3, 60 min incubation with DTT and PHQ. (B)
Reconstituted telomerase was incubated with or without PHQ (50 µM) and increasing
concentrations of DTT for 60 min prior to telomerase assay. Lane 1, DMSO and PHQ; lane
2, PHQ and 500 nM DTT; lane 3, PHQ and 50 µM DTT; lane 4, PHQ and 5 mM DTT.
Telomerase activity was measured by direct primer extension assay, percent telomerase
activity was determined by comparison with the DMSO-only control, and products were
normalized to a loading control, LC as described in the legend of Figure 2. Percent activities
are from three independent experiments (average SD < 10%).
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Catalase protects telomerase from inhibition by PHQ in the presence of DTT. Reconstituted
telomerase was incubated with PHQ in the presence or absence of catalase, and telomerase
activity was determined by direct primer extension assay. Lane 1, DMSO only; lane 2,
telomerase was incubated with PHQ (50 µM), DTT (5mM), and catalase (3.5U) for 1hr; lane
3, telomerase was incubated with PHQ (50 µM) and DTT (5mM) for 1hr; lane 4, telomerase
was incubated with PHQ (50 µM) and DTT (5mM) for 1hr prior to addition of catalase
(3.5U). Percent telomerase activity was determined by comparison with the DMSO-only
control, and products were normalized to a loading control, LC as described in the legend of
Figure 2. Percent activities are from three independent experiments (average SD < 10%).
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Tan II-A produces hydrogen peroxide. (A) Tan II-A (20 µM) was incubated in PBS with 5
mM DTT (blue bar), with 5 mM DTT and 30 U catalase (red bar), or in the absence of DTT
(white bar) for the indicated times. Production of hydrogen peroxide was measured using a
hydrogen peroxide kit from Assay Designs. Data are from two independent experiments,
columns represent the mean and the error bars represent the standard deviation. Increased
hydrogen peroxide at 60 min compared to 30 min was confirmed by one way ANOVA.
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